Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03954938
Other study ID # BED In 38
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date May 15, 2019
Est. completion date December 3, 2021

Study information

Verified date April 2024
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The specific aim of this project is to demonstrate that the decisional analysis/craving regulation aspects of CBT reduce cocaine self-administration in subjects with cocaine use disorder through diminished craving responses. Thirty non-treatment seeking human subjects meeting diagnostic criteria for cocaine use disorder will complete an outpatient, crossover, placebo-controlled study consisting of 1 practice and 9 experimental sessions. In each experimental session, the reinforcing effects of intranasal cocaine will be determined under one of three regulation of craving conditions that simulate CBT decisional analysis (i.e., negative instruction, positive instruction or a neutral "look" condition). After sampling the dose of cocaine available in each session, subjects will complete the craving manipulation assigned to that session, they will then rate their craving and finally they will have the opportunity to earn the sampled dose in a progressive-ratio procedure. We hypothesize that focusing on the negative effects of cocaine use will decrease craving and reduce cocaine self-administration relative to the positive and "look" conditions, and that craving will be positively correlated with self-administration outcomes.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date December 3, 2021
Est. primary completion date December 3, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Current cocaine use Exclusion Criteria: - Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant - Current or past histories of substance use disorder that are deemed by the study physicians to interfere with study completion - History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation - Females not currently using effective birth control - Contraindications to cocaine

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Craving Manipulation
Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
Drug:
Cocaine
The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
Placebo
The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.

Locations

Country Name City State
United States University of Kentucky Laboratory of Human Behavioral Pharmacology Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
William Stoops

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Times Cocaine Was Selected The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects can make 5 choices for each available cocaine dose. Reinforcing effects were measured for each cocaine dose during across the craving manipulation conditions. One test for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.
Secondary Cocaine Craving Cocaine craving was assessed using a 10 point craving questionnaire that asks subjects to rate how much they are craving cocaine at that moment. The minimum craving score is 0 (i.e., no craving), the maximum craving score is 10 (i.e., highest craving). Measured for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.